Syndax Pharmaceuticals offers convertible senior notes due 2031
Syndax Pharmaceuticals is issuing convertible senior notes due 2031 to accredited and institutional investors without SEC registration. The offering allows conversion into cash, common stock, or a combination thereof at the company's election.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day